Navigation Links
DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks
Date:5/24/2013

Toronto, Canada (PRWEB) May 24, 2013

Many factors impact tissues targeting such as protein binding, selective barriers, and uptake or efflux transporters at the blood-tissue barrier. Even when tissue disposition is achieved, activity may be related to unbound fractions in the tissue rather than the total tissue concentration.

A thorough understanding of these disposition challenges is required to guide lead optimization, predict in vivo activity in animal models, and to identify any species-dependent variables that may impact the likely human clinical dose.

In this webinar we will discuss:

  •     A tissue disposition-driven rationale to support lead optimization.
  •     The bioanalytical strategy employed for high efficiency tissue analysis.
  •     For an anti-infective, use of in vitro time-kill and reversibility kinetics to correlate exposure (based on unbound concentrations in tissue) to pharmacodynamic measures that best predict efficacy.
  •     Compound modification and pro-drugging strategies for targeted tissue disposition, and rejuvenation of intellectual property

For more information about this event, visit: http://xtalks.com/DMPK-for-Targeted-Tissue-Delivery.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/5/prweb10765751.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
2. Harvards Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses
3. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
4. First targeted and programmable nanomedicine to show clinical antitumor effects published
5. Phalanx Biotech Group Announces CytoOneArray®, a Targeted Chromosomal Microarray
6. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
7. First-of-its-kind self-assembled nanoparticle for targeted and triggered thermo-chemotherapy
8. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
9. Study identifies targeted molecular therapy for untreatable NF1 tumors
10. University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
11. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
Breaking Biology Technology:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
Breaking Biology News(10 mins):